Status:
COMPLETED
Plasma Melatonin AND Mortality After Acute Myocardial Infarction
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Melatonin
Myocardial Infarction
Eligibility:
All Genders
18+ years
Brief Summary
Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic proper...
Eligibility Criteria
Inclusion
- consecutive patients of acute AMI come to department of cardiology, 301 hospital (Beijing, China),absent of cardiogenic shock, and survival for at least 24 h after percutaneous coronary intervention treatment.
Exclusion
- patients with autoimmune diseases, collagen tissue diseases, drug addiction, radiotherapy, patients receiving immunosuppressive treatment, taking sedatives, antiepileptic drugs, tricyclic antidepressants or any medication known to influence melatonin metabolism, psychiatric sleeping disorders, shift workers, and subjects with jet-lag syndrome
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
732 Patients enrolled
Trial Details
Trial ID
NCT03230630
Start Date
January 1 2013
End Date
January 1 2017
Last Update
July 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.